Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data

INTRODUCTION: Patients with rheumatoid arthritis (RA) are at an increased risk of developing malignancies, but it is unclear whether this increased risk is the result of disease pathobiology or immunosuppressant treatments for RA. This analysis evaluated the potential risk of malignancy in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Emery, Paul, Furst, Daniel E., Kirchner, Petra, Melega, Simone, Lacey, Stuart, Lehane, Patricia B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021875/
https://www.ncbi.nlm.nih.gov/pubmed/31754941
http://dx.doi.org/10.1007/s40744-019-00183-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021875/
https://www.ncbi.nlm.nih.gov/pubmed/31754941
http://dx.doi.org/10.1007/s40744-019-00183-6

Ejemplares similares